about
Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors.Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodiesAssociation of blood bicarbonate and pH with mineral metabolism disturbance and outcome after kidney transplantationResponse to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejectionLifetime ESKD risk stratification for living kidney donor studiesReassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantationTwo-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM studyDevelopment and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection
P50
Q40096366-5510E129-139C-44C8-A8B9-36C73118ED24Q50112302-E95D88C3-8216-41AE-A660-E766C3D4FAEBQ90224907-30B57488-D03F-42EE-9E1A-83E4AA918928Q91079415-A9D7F179-A5B5-448C-9C09-7D53C0FA4752Q91480617-E1315B66-6D8F-4681-B4D7-2BADEC0196BAQ91670365-43B32277-616F-4458-BED6-09B10F3490B6Q92293553-FD8E94D6-949A-486A-84CC-FFBA885110E5Q92453879-BB33A6EB-784E-49F2-9632-E6B9CB40DEC8Q93333092-D2B0B9A2-5810-41C1-B580-C001D22CB1E0
P50
description
researcher
@en
name
C Legendre
@en
type
label
C Legendre
@en
prefLabel
C Legendre
@en
P31
P496
0000-0002-1743-2948